Today, Thursday, October 30, 2025, Oculis Holding AG (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in ophthalmology and neuro-ophthalmology, announced the completion of a share offering of approximately ISK 13.6 billion (USD 110 million).
Oculis intends to use the net proceeds from the financing to advance and accelerate the development of its novel neuroprotective clinical candidate, Privosegtor in acute optic neuritis (AON) and non-arteritic anterior ischemic optic neuropathy (NAION), as well as for working capital and general corporate purposes.
J.P. Morgan, Leerink Partners and Pareto Securities are acting as joint bookrunning managers for the Offering. Van Lanschot Kempen is acting as manager for the Offering. Arctica Finance is acting as financial advisor for the Offering.
Oculis is a global biopharmaceutical company (Nasdaq: OCS; XICE: OCS) focused on innovations addressing neuro-ophthalmic conditions with significant unmet medical needs. Oculis’ highly differentiated late-stage clinical pipeline includes three core product candidates: Privosegtor, a neuroprotective candidate in the PIONEER program which consists of studies intended to support registration for treatment in optic neuropathies like acute optic neuritis (AON) and non-arteritic anterior ischemic optic neuropathy (NAION), with potentially broad clinical applications in various other neuro-ophthalmic and neurological diseases; OCS-01, an eye drop in pivotal registration studies, aiming to become the first non-invasive topical treatment for diabetic macular edema (DME); and Licaminlimab, a novel, topical anti-TNFα in Phase 2, which is being developed with a genotype-based approach to drive personalized medicine in dry eye disease (DED). Headquartered in Switzerland with operations in the U.S. and Iceland, Oculis is led by an experienced management team with a successful track record and supported by leading international healthcare investors.
